• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Dexcom Appoints Jon Coleman as Chief Commercial Officer

    3/25/25 4:05:00 PM ET
    $DXCM
    $MASI
    $PFE
    Medical/Dental Instruments
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $DXCM alert in real time by email

    DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for Dexcom's global commercial organization, including global sales, marketing and customer experience.

    Mr. Coleman joins Dexcom with more than 30 years of global commercial leadership experience across multiple healthcare segments and channels. Mr. Coleman served as an executive officer of Masimo Corporation (NASDAQ:MASI), where he held roles of increasing responsibility across his fifteen-year tenure. This included serving as president of Masimo's commercial teams where he oversaw the consolidation of its worldwide hospital sales, OEM, alternate care sales, and clinical teams along with the customer service and hospital conversion teams. Mr. Coleman also held significant roles at Pfizer's (NYSE:PFE) Consumer Healthcare business, leading as vice president and general manager of Canada and the Caribbean region after several years of regional leadership in Asia and Latin America. Across his various roles at these organizations, Mr. Coleman established a track record of scaling operations, developing innovative products, entering new markets, and delivering strong growth performance.

    "Jon has demonstrated the ability to lead organizations through the complexities of global healthcare with consistently strong performance across a variety of sectors and channels," said Kevin Sayer, chairman, president and chief executive officer at Dexcom. "This broad experience across market segments and regions provides a great fit as we look to capitalize on Dexcom's incredible growth opportunity."

    "Dexcom's commitment to drive innovation in glucose biosensing and its unique long-term growth opportunity make the chief commercial officer role an incredible opportunity," said Mr. Coleman. "I am excited to lead this great team at a key point in the company's history and execute on the company's ambitious vision to empower greater health around the world."

    About Jon Coleman

    Prior to his role as president – Worldwide OEM & Global Health at Masimo, Mr. Coleman held several roles of increasing responsibility at Masimo including president – Worldwide Sales, Professional Services, Medical Affairs, and OEM and president – International. Before joining Masimo, he was general manager – Americas region for Targus Group International, Inc. Before that, Mr. Coleman spent more than a decade in leadership of the Consumer Healthcare business at Pfizer, revitalizing growth as vice president and general manager – Canada and Caribbean region and driving double-digit growth as region director – Asia. Before joining Pfizer, Mr. Coleman began his career with roles at the Procter & Gamble Company and Bain & Company.

    Mr. Coleman earned an M.B.A. from Harvard Business School and a Bachelor of Arts degree in International Relations from Brigham Young University.

    About DexCom, Inc.

    Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

    Dexcom. Discover what you're made of. For more information, visit www.dexcom.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250325396614/en/

    Media Contact

    James McIntosh

    619-884-2118

    [email protected]



    Investor Contact

    Sean Christensen

    858-203-6657

    [email protected]

    Get the next $DXCM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $DXCM
    $MASI
    $PFE

    CompanyDatePrice TargetRatingAnalyst
    DexCom Inc.
    $DXCM
    6/16/2025$102.00Buy
    Truist
    DexCom Inc.
    $DXCM
    5/30/2025$104.00Buy
    Goldman
    Pfizer Inc.
    $PFE
    4/22/2025$24.00Neutral
    Cantor Fitzgerald
    DexCom Inc.
    $DXCM
    4/10/2025$85.00Outperform
    Mizuho
    DexCom Inc.
    $DXCM
    2/3/2025$85.00 → $115.00Neutral → Buy
    Redburn Atlantic
    DexCom Inc.
    $DXCM
    1/16/2025$86.00 → $104.00Neutral → Outperform
    Robert W. Baird
    Masimo Corporation
    $MASI
    12/27/2024$170.00 → $194.00Outperform
    Raymond James
    Pfizer Inc.
    $PFE
    12/10/2024$29.00Neutral
    BofA Securities
    More analyst ratings

    $DXCM
    $MASI
    $PFE
    SEC Filings

    See more
    • SEC Form 10-Q filed by DexCom Inc.

      10-Q - DEXCOM INC (0001093557) (Filer)

      7/30/25 5:19:57 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • DexCom Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

      8-K - DEXCOM INC (0001093557) (Filer)

      7/30/25 4:02:50 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • SEC Form 144 filed by DexCom Inc.

      144 - DEXCOM INC (0001093557) (Subject)

      7/28/25 4:29:23 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care

    $DXCM
    $MASI
    $PFE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Chief HR Officer Stern Sadie sold $130,459 worth of shares (1,466 units at $88.99), decreasing direct ownership by 1% to 106,689 units (SEC Form 4)

      4 - DEXCOM INC (0001093557) (Issuer)

      7/29/25 4:18:05 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Director Foletta Mark G sold $234,217 worth of shares (2,750 units at $85.17) (SEC Form 4)

      4 - DEXCOM INC (0001093557) (Issuer)

      7/17/25 4:08:36 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • EVP, Chief Legal Officer Brown Michael Jon sold $43,015 worth of shares (500 units at $86.03), decreasing direct ownership by 0.53% to 94,602 units (SEC Form 4)

      4 - DEXCOM INC (0001093557) (Issuer)

      7/17/25 4:03:07 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care

    $DXCM
    $MASI
    $PFE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Dexcom Reports Second Quarter 2025 Financial Results, Updates Full Year 2025 Guidance and Announces CEO Succession Plan

      DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights: Revenue grew 15% year-over-year to $1.157 billion on a reported basis and 15% year-over-year on an organic1 basis. U.S. revenue grew 15% and international revenue grew 16% on a reported basis and 14% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $212.6 million or 18.4% of revenue, an increase of 270 basis points compared to the second quarter of 2024. Non-GAAP operating income* of $221.8 million or 19.2% of reported revenue, a decrease of 30 basis points compared to the second quarter of 2024. S

      7/30/25 4:02:00 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Dexcom Launches Revolutionary AI-Powered Meal Logging Feature Across Glucose Biosensing Portfolio

      The new AI-powered Smart Food Logging feature supports greater personalized insights into how meals are impacting glucose levels Users can now take a photo of their food in their Stelo or Dexcom G7 app where AI will automatically identify the ingredients and populate the meal description DexCom, Inc., the global leader in glucose biosensing, announced today it has released a new AI-powered photo meal logging feature to Stelo, the first over-the-counter glucose biosensor cleared1 by the FDA in the United States, following the feature's launch on Dexcom G7 earlier this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2025

      7/28/25 8:30:00 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union

      Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to 2024-2025 COVID-19 vaccine formulationsUpon authorization by the European Commission (EC), the LP.8.1-adapted COVID-19 vaccine will be available for individuals 6 months of age and olderTo date, over a billion adults and children around the world have received the Pfizer-BioNTech COVID-19 vaccine, which continues to demonstrate a favorable safety and efficacy profile supported by extensive real-world evidence, clinical, non-clinical, pharmacovigilance and manufacturing dataDoses will be ready to sh

      7/25/25 2:30:00 AM ET
      $BNTX
      $PFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $DXCM
    $MASI
    $PFE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Blaylock Ronald E bought $499,072 worth of shares (19,457 units at $25.65), increasing direct ownership by 236% to 27,707 units (SEC Form 4)

      4 - PFIZER INC (0000078003) (Issuer)

      2/14/25 5:16:36 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Gottlieb Scott bought $28,240 worth of shares (1,000 units at $28.24), increasing direct ownership by 11% to 10,000 units (SEC Form 4)

      4 - PFIZER INC (0000078003) (Issuer)

      10/31/24 4:06:54 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gottlieb Scott bought $79,401 worth of shares (3,000 units at $26.47), increasing direct ownership by 50% to 9,000 units (SEC Form 4)

      4 - PFIZER INC (0000078003) (Issuer)

      12/19/23 9:31:01 AM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DXCM
    $MASI
    $PFE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $DXCM
    $MASI
    $PFE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • Truist initiated coverage on Dexcom with a new price target

      Truist initiated coverage of Dexcom with a rating of Buy and set a new price target of $102.00

      6/16/25 7:46:45 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Goldman initiated coverage on Dexcom with a new price target

      Goldman initiated coverage of Dexcom with a rating of Buy and set a new price target of $104.00

      5/30/25 8:41:14 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Cantor Fitzgerald initiated coverage on Pfizer with a new price target

      Cantor Fitzgerald initiated coverage of Pfizer with a rating of Neutral and set a new price target of $24.00

      4/22/25 8:03:45 AM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • October 25, 2024 - FDA Roundup: October 25, 2024

      For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

      10/25/24 2:48:21 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for HYMPAVZI issued to PFIZER INC

      Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

      10/15/24 2:57:27 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • October 11, 2024 - FDA Approves New Treatment for Hemophilia A or B

      For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro

      10/11/24 2:12:15 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DXCM
    $MASI
    $PFE
    Leadership Updates

    Live Leadership Updates

    See more
    • Dexcom Unveils Season 4 Roster for Game-Changing NIL Program at Signing Day Camp Hosted by Mark Andrews

      Dexcom's first-of-its-kind NIL program welcomes 13 new athletes and eight returning team members, including San Diego State University basketball standout Miles Byrd and Alabama A&M University's Shelomi Sanders The trailblazing program empowers college athletes with Type 1 diabetes to break barriers in sports and inspire their communities, as showcased at the Dexcom U Signing Day Camp, a new addition to the program, earlier this month DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the launch of the fourth season of Dexcom U, the company's one-of-a-kind NIL (Name, Image and Likeness) program exclusively for college athletes with diabetes. This pr

      7/17/25 8:30:00 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Masimo Joins Innovators' Network at American Heart Association Center for Health Technology & Innovation

      American Heart Association Consortium Advances Development of Evidence-based Health Tech Solutions Masimo (NASDAQ:MASI), a global medical technology company that develops and manufactures innovative noninvasive monitoring solutions, has joined the American Heart Association Center for Health Technology & Innovation's (the Center) Innovators' Network. The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708674775/en/Masimo is a member of the American Heart Association's Innovators' Network The Innovators' N

      7/8/25 8:00:00 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Dexcom Launches First Nationwide Search for College Athletes With Diabetes to Join Season Four of Dexcom U

      Dexcom's first-of-its-kind NIL program is accepting nominations for passionate and inspiring college athletes with diabetes for its 2025 roster now through May 23. Selected athletes will be invited to the Dexcom U Signing Day Camp this summer, hosted by Dexcom Warrior and Baltimore Ravens tight end Mark Andrews. DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the return of Dexcom U – its one-of-a-kind Name, Image and Likeness program exclusively for college athletes with diabetes – for an expanded fourth season, including the first-ever nationwide open call for passionate and inspiring college athletes to join its roster. This press release features

      4/22/25 8:00:00 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care

    $DXCM
    $MASI
    $PFE
    Financials

    Live finance-specific insights

    See more
    • Dexcom Reports Second Quarter 2025 Financial Results, Updates Full Year 2025 Guidance and Announces CEO Succession Plan

      DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights: Revenue grew 15% year-over-year to $1.157 billion on a reported basis and 15% year-over-year on an organic1 basis. U.S. revenue grew 15% and international revenue grew 16% on a reported basis and 14% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $212.6 million or 18.4% of revenue, an increase of 270 basis points compared to the second quarter of 2024. Non-GAAP operating income* of $221.8 million or 19.2% of reported revenue, a decrease of 30 basis points compared to the second quarter of 2024. S

      7/30/25 4:02:00 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Masimo to Report Second Quarter 2025 Financial Results after Market Close on Tuesday, August 5

      Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET) Masimo (NASDAQ:MASI) will release second quarter 2025 financial results for the period ended June 28, 2025, after the market closes on Tuesday, August 5, 2025. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Katie Szyman, Chief Executive Officer, and Micah Young, Chief Financial Officer. To register for the conference call and receive the dial-in number, please use the link below. Upon registering, each participant will be provided with details including the dial-in number and a registrant ID number. Reminders about the call will also be sent to registered partic

      7/22/25 9:00:00 AM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Dexcom Schedules Second Quarter 2025 Earnings Release and Conference Call for July 30, 2025 at 4:30 p.m. Eastern Time.

      DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2025 financial results after market close on Wednesday, July 30, 2025. Management will hold a conference call to review the company's second quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference. To listen to the conference call, please dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and use the confirmation ID "9430114" approximately five minutes prior to the

      7/1/25 8:30:00 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care

    $DXCM
    $MASI
    $PFE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Masimo Corporation

      SC 13D/A - MASIMO CORP (0000937556) (Subject)

      9/25/24 4:01:23 PM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Masimo Corporation

      SC 13D/A - MASIMO CORP (0000937556) (Subject)

      8/30/24 4:56:53 PM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Masimo Corporation

      SC 13D/A - MASIMO CORP (0000937556) (Subject)

      7/17/24 5:29:36 PM ET
      $MASI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care